Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content. Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

Carfilzomib Is Not Superior To Bortezomib In Delaying Multiple Myeloma Progression After Initial Treatment

(Mayo Clinic) May 28, 2020 - Carfilzomib, a proteasome inhibitor used in combination with Lenalidomide, an immune modulating drug, is not superior to Bortezomib, Lenalidomide and Dexamethasone, in the initial treatment of multiple myeloma according to the results of phase 3 clinical trial presented today at #ASCO20 scientific program by Shaji Kumar, M.D. , a hematologist at Mayo Clinic.

City of Hope Physicians Present Innovative Cancer Research at ASCO20 Virtual Session

(City of Hope) May 30, 2020 - A targeted therapy for colorectal cancer and an immunotherapy drug for head and neck cancer are just some of the innovative treatments City of Hope doctors are presenting at this year’s ASCO20 Virtual Scientific Program, which starts today and ends May 31.

Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer

(Pfizer) May 29, 2020 - As announced today by the Austrian Breast & Colorectal Cancer Study Group and the Alliance Foundation Trials, LLC, Pfizer Inc. reports that following a preplanned efficacy and futility analysis, the independent Data Monitoring Committee (DMC) of the collaborative Phase 3 early breast cancer PALbociclib CoLlaborative Adjuvant Study (PALLAS) determined that the trial is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival (iDFS). Patients currently receiving palbociclib in the study will be advised about next steps by their physicians and long-term follow up of all patients will proceed as planned. No unexpected new safety signals were observed in patients receiving palbociclib.

Imfinzi Plus Tremelimumab Demonstrated Promising Clinical Activity And Tolerability In Patients With Advanced Liver Cancer

(AstraZeneca) May 29, 2020 - Data presented at ASCO showed patients treated with a single, priming dose of tremelimumab plus Imfinzi achieved longest median survival among regimens tested.

Traders Sift Through Virtual Cancer Meeting’s Winners and Losers

(Bloomberg) May 29, 2020 - Biotechnology stocks saw broad swings Friday morning as investors worked their way through a deluge of data from cancer drug developers presenting at the American Society of Clinical Oncology’s virtual annual meeting.

Lilly’s CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

(Lilly) May 29, 2020 - Eli Lilly and Company today announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA® (ramucirumab injection, 10 mg/mL solution), in combination with erlotinib, for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. With this approval, CYRAMZA has now received six FDA approvals to treat certain types of lung, liver, stomach and colorectal cancers.

ImmunoGen Presents Initial Data at ASCO from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status

(ImmunoGen) May 29, 2020 - ImmunoGen, Inc. today announced initial data from the FORWARD II study evaluating mirvetuximab soravtansine in combination with Avastin® (bevacizumab) in patients with medium and high folate receptor alpha (FRα)-expressing recurrent ovarian cancer for whom a non-platinum based combination regimen is appropriate.

SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction (EGJ), Lung, and Head and Neck Cancers – Late Stage Development Initiated in EGJ Cancer

(Adaptimmune) May 29, 2020 - New Phase 2 trial in EGJ cancer planned for 1H 2021, after first two patients treated responded to next-generation ADP-A2M4CD8 therapy. Durability and efficacy data presented at ASCO support potential for SPEARHEAD-1 as a registrational trial for sarcoma - commercial launch planned in the US in 2022.

Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader ARV-110 in Patients with Metastatic Castration-Resistant Prostate Cancer

(Arvinas) May 29, 2020 - Clear efficacy signal with two ongoing confirmed PSA responses, including one associated with a confirmed RECIST response.

Final Prosper Results Show Xtandi® (Enzalutamide) Significantly Extends Overall Survival In Men With Non-Metastatic Castration-Resistant Prostate Cancer

(Pfizer) May 29, 2020 - Data simultaneously published in the New England Journal of Medicine and presented during the virtual scientific program of the 2020 ASCO Annual Meeting. Pfizer Inc. and Astellas Pharma Inc. have announced final results from the overall survival (OS) analysis of the Phase 3 PROSPER trial, which evaluated XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) versus placebo plus ADT in men with non-metastatic castration-resistant prostate cancer (nmCRPC).